Alnylam Pharmaceuticals, Inc.
ALNY Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$224.03
KIRA · Stoqly’s AI analyst, in plain words
- Alnylam Pharmaceuticals, Inc. had $3.7B of revenue in fiscal 2025, up 65.2% on the year before. Over five years, revenue changed +49.8% a year on average.
- Its operating margin was 13.5%, up 21.4 pts: of every 100 in sales, about 14 is left after running the business.
- Alnylam Pharmaceuticals, Inc. made $314M of net profit in fiscal 2025.
- Free cash flow was $465M in fiscal 2025, 12.5% of revenue.
Market cap
$31.0B
P/E
96.2x
Revenue
$3.7B
Net income
$314M
Free cash flow
$465M
Operating margin
13.5%
Alnylam Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+65.2%
Yes. Sales grew 65.2% last year.
Does it make a profit?
8.4%
A little. It keeps 8.4% of every sale as profit.
Does profit turn into cash?
12.5%
Yes. 12.5% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
96.2x
One share costs 96.2 times its yearly profit per share.
What Alnylam Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- ALNYLAM PHARMACEUTICALS, INC.
- CIK
- 0001178670
Alnylam Pharmaceuticals, Inc. · ALNY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $844M | $1.0B | $1.8B | $2.2B | $3.7B |
| Revenue growth | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% |
| Gross margin | 86.4% | 86.5% | 85.3% | 86.4% | 81.8% |
| Operating margin | −83.9% | −75.7% | −15.4% | −7.9% | 13.5% |
| Net income | −$853M | −$1.1B | −$440M | −$278M | $314M |
| Net margin | −101.0% | −109.0% | −24.1% | −12.4% | 8.4% |
| Diluted EPS | −$7.20 | −$9.30 | −$3.52 | −$2.18 | $2.33 |
| Cash | |||||
| Cash from operations | −$642M | −$541M | $104M | −$8.3M | $524M |
| Capital expenditure | $76.4M | $72.1M | $62.2M | $34.3M | $58.7M |
| Free cash flow | −$718M | −$613M | $41.9M | −$42.6M | $465M |
| FCF margin | −85.0% | −59.1% | 2.3% | −1.9% | 12.5% |
| Share count change | 3.0% | 2.7% | 2.6% | 2.2% | 5.5% |
| Debt and strength | |||||
| Cash and short-term investments | $2.4B | $2.2B | $2.4B | $2.7B | $2.9B |
| Debt incl. finance leases | $676M | — | — | — | — |
| Shareholders' equity | $588M | −$158M | −$221M | $67.1M | $789M |
| Current ratio | 4.0x | 3.5x | 3.1x | 2.8x | 2.8x |
| Interest coverage | −5.0x | −5.0x | −2.3x | −1.2x | 2.0x |
| Returns and quality | |||||
| Return on equity | −106.3% | −526.1% | — | — | 73.3% |
| Return on tangible equity | −145.0% | — | — | −414.6% | 39.8% |
| Piotroski F-score | 4 | 3 | 4 | 4 | 5 |
| Altman Z'' | −2.2 | −4.0 | −3.1 | −2.6 | −0.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$44.0M
8 insiders
Of sales under plans
63%
$27.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alnylam Pharmaceuticals, Inc. · ALNY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $224.03 a share, the company is worth $31.0B: 96.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001178670). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.